Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABSK192
- Development stage
- Preclinical
- Lead developer
- Abbisko Therapeutics
- Modality
- Small Molecules
01
Overview
ABSK192 is an investigational, brain-penetrant (CNS-penetrant), selective small molecule inhibitor of cyclin-dependent kinase 4 (CDK4) developed by Abbisko Therapeutics. It is designed to offer an enhanced therapeutic profile for the treatment of cancer, demonstrating superior CDK4 potency and good selectivity over CDK6 to minimize CDK6-mediated toxicity. In preclinical studies, ABSK192 has shown potent anti-tumor activity and favorable pharmacokinetic properties, supporting its potential as a differentiated therapeutic option, particularly for patients with brain metastases. It is currently in the IND-enabling (preclinical) stage of development for solid tumors.
02
Targets
CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on ABSK192.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABSK192.